Skip to main content
Premium Trial:

Request an Annual Quote

C-Path, Centogene Partner to Advance Lysosomal Disease Drug Development

NEW YORK – Critical Path Institute (C-Path) and Centogene signed a memorandum of understanding (MOU) outline a strategic partnership to jointly improve drug development for rare lysosomal diseases.

The MOU encompasses areas of potential collaboration between the two, including data enrichment or linkage for lysosomal disorders that include Niemann-Pick disease type C, Gaucher disease types 2 and 3, and mucopolysaccharidosis type II, and providing genetic testing services for clinical trials or observational studies. It further includes sample analysis reporting services for diagnostics performed by Centogene or other labs via CentoCloud and limited access to Centogene's Biodatabank for analyzing patient data from Centogene's Critical Path for Lysosomal Diseases (CPLD) Consortium projects. The MOU also covers joint cobranding efforts.

"This partnership … will enable us to combine our expertise and resources to overcome significant barriers in [lysosomal disease] research and drug development," Krista Casazza, scientific director of the CPLD Consortium, said in a statement.

Earlier this year, Centogene announced a collaboration with the Michael J. Fox Foundation to study genetic risk factors associated with Parkinson's disease.